Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.

Literature DB >> 19949060

Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.

Hélène Savini, Jean Baptiste Souraud, Sébastien Briolant, Eric Baret, Rémy Amalvict, Christophe Rogier, Bruno Pradines.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2009 PMID： 19949060 PMCID： PMC2812141 DOI： 10.1128/AAC.01006-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

13 in total

1. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors: Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal: Antimicrob Agents Chemother Date: 2007-05-14 Impact factor: 5.191

2. Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Authors: Rina P M Wong; Timothy M E Davis
Journal: Antimicrob Agents Chemother Date: 2009-03-02 Impact factor: 5.191

3. Statins alone are ineffective in cerebral malaria but potentiate artesunate.

Authors: Anne-Lise Bienvenu; Stéphane Picot
Journal: Antimicrob Agents Chemother Date: 2008-09-08 Impact factor: 5.191

4. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.

Authors: E L Posvar; L L Radulovic; D D Cilla; L R Whitfield; A J Sedman
Journal: J Clin Pharmacol Date: 1996-08 Impact factor: 3.126

5. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study.

Authors: V Borek-Dohalský; J Huclová; B Barrett; B Nemec; I Ulc; I Jelínek
Journal: Anal Bioanal Chem Date: 2006-08-22 Impact factor: 4.142

Review 6. Pathogenesis of malaria and clinically similar conditions.

Authors: Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal: Clin Microbiol Rev Date: 2004-07 Impact factor: 26.132

7. Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria.

Authors: Maud Henry; Sandrine Alibert; Meili Baragatti; Joel Mosnier; Eric Baret; Rémy Amalvict; Eric Legrand; Thierry Fusai; Jacques Barbe; Christophe Rogier; Jean-Marie Pagès; Bruno Pradines
Journal: Med Chem Date: 2008-09 Impact factor: 2.745

8. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.

Authors: Peter S Kruger; Noelle M Freir; Bala Venkatesh; Thomas A Robertson; Michael S Roberts; Mark Jones
Journal: Intensive Care Med Date: 2008-11-26 Impact factor: 17.440

9. Molecular surveillance for multidrug-resistant Plasmodium falciparum, Cambodia.

Authors: Naman K Shah; Alisa P Alker; Rithy Sem; Agustina Ika Susanti; Sinuon Muth; Jason D Maguire; Socheat Duong; Frederic Ariey; Steven R Meshnick; Chansuda Wongsrichanalai
Journal: Emerg Infect Dis Date: 2008-10 Impact factor: 6.883

10. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment.

Authors: Verena Ilona Carrara; Julien Zwang; Elizabeth A Ashley; Ric N Price; Kasia Stepniewska; Marion Barends; Alan Brockman; Tim Anderson; Rose McGready; Lucy Phaiphun; Stephane Proux; Michele van Vugt; Robert Hutagalung; Khin Maung Lwin; Aung Pyae Phyo; Piyanuch Preechapornkul; Mallika Imwong; Sasithon Pukrittayakamee; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal: PLoS One Date: 2009-02-23 Impact factor: 3.240

11 in total

1. Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin.

Authors: Jérôme Dormoi; Aurélie Pascual; Sébastien Briolant; Rémy Amalvict; Serge Charras; Eric Baret; Emilie Huyghues des Etages; Michel Feraud; Bruno Pradines
Journal: Antimicrob Agents Chemother Date: 2012-03-05 Impact factor: 5.191

2. Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors: Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal: Malar J Date: 2010-05-25 Impact factor: 2.979

3. Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast.

Authors: Nathalie Wurtz; Aurélie Pascual; Adeline Marin-Jauffre; Housem Bouchiba; Nicolas Benoit; Marc Desbordes; Maryse Martelloni; Vincent Pommier de Santi; Georges Richa; Nicolas Taudon; Bruno Pradines; Sébastien Briolant
Journal: Malar J Date: 2012-05-02 Impact factor: 2.979

4. Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage.

Authors: Zacharie Taoufiq; Paco Pino; Nadine N'dilimabaka; Issam Arrouss; Serge Assi; Florent Soubrier; Angelita Rebollo; Dominique Mazier
Journal: Malar J Date: 2011-02-28 Impact factor: 2.979

5. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Authors: Jean-Baptiste Souraud; Sébastien Briolant; Jérome Dormoi; Joel Mosnier; Hélène Savini; Eric Baret; Rémy Amalvict; Raoulin Soulard; Christophe Rogier; Bruno Pradines
Journal: Malar J Date: 2012-01-10 Impact factor: 2.979

6. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Authors: Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal: Malar J Date: 2013-04-15 Impact factor: 2.979